Korro Bio is pioneering RNA editing to deliver the future of medicine. Korro Bio’s proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), harnesses the body’s natural base editing system — specifically ADAR (Adenosine Deaminase Acting on RNA) — to make precise, single-base edits to RNA. OPERA can repair disease-causing mutations at the RNA level, in addition to creating therapeutically beneficial versions of proteins to improve patient outcomes. Korro Bio is prioritizing therapeutic indications across tissues where safe and targeted editing of messenger RNA could provide unique benefits over other modalities in development.
| Headquarters | Cambridge, MA |
| Website | www.korrobio.com |
| Pipeline | Preclinical |
| @korrobio |